Show simple item record

dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorPectasides, Dimitriosen
dc.contributor.authorKalogera-Fountzila, Annaen
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorBafaloukos, Dimitriosen
dc.contributor.authorLambropoulos, S.en
dc.contributor.authorPapadopoulos, S.en
dc.contributor.authorKourea, H.en
dc.contributor.authorMarkopoulos, C.en
dc.contributor.authorLinardou, H.en
dc.contributor.authorMavroudis, D.en
dc.contributor.authorBriassoulis, E. Chen
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorRazi, E. D.en
dc.contributor.authorKosmidis, Paraskevas A.en
dc.contributor.authorGogas, H.en
dc.creatorFountzilas, Georgeen
dc.creatorPectasides, Dimitriosen
dc.creatorKalogera-Fountzila, Annaen
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorKalofonos, H. P.en
dc.creatorPapadimitriou, C.en
dc.creatorBafaloukos, Dimitriosen
dc.creatorLambropoulos, S.en
dc.creatorPapadopoulos, S.en
dc.creatorKourea, H.en
dc.creatorMarkopoulos, C.en
dc.creatorLinardou, H.en
dc.creatorMavroudis, D.en
dc.creatorBriassoulis, E. Chen
dc.creatorPavlidis, Nicholasen
dc.creatorRazi, E. D.en
dc.creatorKosmidis, Paraskevas A.en
dc.creatorGogas, H.en
dc.date.accessioned2018-06-22T09:53:06Z
dc.date.available2018-06-22T09:53:06Z
dc.date.issued2005
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41662
dc.description.abstractPaclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for cancer treatment. This multicenter phase II trial treated 68 patients with advanced breast cancer with paclitaxel (175 mg/m2 over 3 h) and 3-weekly carboplatin (area under the curve of 6) for six cycles, and 250 mg/day gefitinib orally. Median age was 57 (range 35-77) years, patients had performance status 0 (69.1%), 1 (27.9%) 2 (2.9%), 82.4% of patients had visceral metastases and 63.2% had received adjuvant chemotherapy. Forty-eight (70.6%) patients completed six cycles of chemotherapy and 20 (29.4%) patients discontinued treatment (seven [10.3%] due to disease progression, seven [10.3%] due to toxicity, five [7.4%] withdrew consent and one [1.5%] died after the first cycle). Sixty-three (92.7%) patients were evaluable for response; nine (13.2%) had complete responses, 30 (44.1%) had partial responses, 21 (30.9%) had stable disease and three (4.4%) had disease progression. Grade 3/4 adverse events in ≥5% of patients except of alopecia, included neutropenia (17.7%), anemia (10.3%), diarrhea (7.4%), thrombocytopenia (5.9%) and peripheral neuropathy (5.9%). Of those tumor biopsies available for immunohistochemical analysis (n=60), 5.0% were positive and 35.0% negative for expression of all HER-family receptors. Comparable numbers of tumor biopsies were nuclear p27 kipl positive and negative (39.7 and 42.7%, respectively), with the majority (72.1%) negative for cytoplasmic p27kipl. The observed efficacy data in this study were similar to those reported for the combination of paclitaxel and carboplatin alone. © Springer 2005.en
dc.language.isoengen
dc.sourceBreast cancer research and treatmenten
dc.subjectArticleen
dc.subjectFemaleen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast canceren
dc.subjectBreast neoplasmsen
dc.subjectControlled studyen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectCancer growthen
dc.subjectNeoplasm stagingen
dc.subjectPriority journalen
dc.subjectAlopeciaen
dc.subjectAnemiaen
dc.subjectAnorexiaen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectArthralgiaen
dc.subjectClinical trialen
dc.subjectConstipationen
dc.subjectControlled clinical trialen
dc.subjectDiarrheaen
dc.subjectDrug efficacyen
dc.subjectFatigueen
dc.subjectInfectionen
dc.subjectMyalgiaen
dc.subjectNeutropeniaen
dc.subjectPhase 2 clinical trialen
dc.subjectStomatitisen
dc.subjectThrombocytopeniaen
dc.subjectTreatment outcomeen
dc.subjectArea under the curveen
dc.subjectCancer stagingen
dc.subjectDrug hypersensitivityen
dc.subjectCarboplatinen
dc.subjectAge distributionen
dc.subjectImmunohistochemistryen
dc.subjectVomitingen
dc.subjectCancer adjuvant therapyen
dc.subjectNauseaen
dc.subjectPhase 1 clinical trialen
dc.subjectPeripheral neuropathyen
dc.subjectPaclitaxelen
dc.subjectTumor biopsyen
dc.subjectAdvanced breast canceren
dc.subjectCyclin dependent kinase inhibitor 1ben
dc.subjectCytopeniaen
dc.subjectEpidermal growth factor receptor kinaseen
dc.subjectEpidermal growth factor receptor kinase inhibitoren
dc.subjectGefitiniben
dc.subjectInformed consenten
dc.subjectIressaen
dc.subjectQuinazolinesen
dc.subjectRashen
dc.titlePaclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Groupen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s10549-005-0322-y
dc.description.volume92
dc.description.issue1
dc.description.startingpage1
dc.description.endingpage9
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidKalogera-Fountzila, Anna [0000-0002-6801-3129]
dc.contributor.orcidKalofonos, H. P. [0000-0002-3286-778X]
dc.gnosis.orcid0000-0002-2195-9961|0000-0002-6801-3129
dc.gnosis.orcid0000-0002-3286-778X


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record